FA
LGND icon

Financial Advantage’s Ligand Pharmaceuticals LGND Stock Holding History

Financial Advantage’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-240
Closed -$6K – 238
2013
Q3 		$6K Hold
240
– – 0.01% 160
2013
Q2 		$6K Buy
+240
New +$4.32K 0.01% 165

Other funds holding LGND

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Financial Advantage's LGND Position: Q4 2013 in Review

Financial Advantage sold out of Ligand Pharmaceuticals (LGND) in Q4 2013, closing a stake of 240 shares — an estimated $6K sold.

Financial Advantage first reported a position in LGND in Q2 2013 and held it in 2 quarters. The position peaked at $6K in Q3 2013. 165 funds tracked by Wall St. Rank hold LGND as of Q4 2013.

  • Financial Advantage reported no remaining Ligand Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Financial Advantage sold 240 Ligand Pharmaceuticals shares in Q4 2013, an estimated $6K.
  • Financial Advantage first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Financial Advantage's Ligand Pharmaceuticals position peaked at $6K in Q3 2013.
  • 165 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2013.

Based on Financial Advantage's 13F filing for Q4 2013, filed 12 Feb 2014.